多西紫杉醇联合希罗达治疗晚期乳腺癌33例临床观察  

Clinical Observation of 33 Patients with Advanced Breast Cancer Treated with Docetaxel and Xeloda

作　　者：王彩玲[1] 王俊生[1] 王静[1] 

机构地区：[1]安阳市肿瘤医院内一科,河南安阳455000

出　　处：《肿瘤基础与临床》2009年第1期38-39,共2页journal of basic and clinical oncology

摘　　要：目的观察多西紫杉醇联合希罗达治疗晚期乳腺癌的疗效及毒副反应。方法多西紫杉醇75mg/m2,静滴1h,d1;希罗达2500mg/m2,口服,分早晚2次餐后服用,连用14d,21d为1周期,治疗2～4周期后评价疗效及毒副反应。结果33例均可评价疗效,完全缓解(CR)4例,部分缓解(PR)12例,稳定(SD)11例,进展(PD)6例,总有效率(CR+PR)48.5%。主要毒副反应为骨髓抑制、胃肠道反应、手足综合征。结论多西紫杉醇联合希罗达治疗晚期乳腺癌疗效较好,毒副反应轻,耐受性好,是晚期乳腺癌的有效治疗方案。Objective To study the efficacy and toxicities of Decetaxel combined with Xeloda in treating patients with advanced breast cancer. Methods Docetaxel was given 70 mg/m^2 on day 1, and Xeloda was given 2 500 mg/m^2 twice a day for 14 days. The chemotherapy was repeated every 3 weeks, the efficacy and toxicities were reviewed after 2 to 4 cycles of chemotherapy. Results The 33 patients were evaluable for response. CR 4 cases, PR 12 cases, SD 11 cases, and PD 6 cases. The overall response rate was 48.5% （16/33）. The main toxicities included myelosappression, gastrointestinal toxicities, hand-foot syndrome. Conclusion Docetaxed and Xeloda is effective in the treatment of patients with advanced breast cancer, the toxicity was acceptable and it may be a effective regimen.

关 键 词：多西紫杉醇 希罗达 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]